Opko Health Inc.  

(Public, NYSE:OPK)   Watch this stock  
Find more results for OPK
+0.25 (2.31%)
Nov 25 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 10.89 - 11.09
52 week 8.16 - 19.20
Open 10.94
Vol / Avg. 2.61M/5.62M
Mkt cap 6.04B
P/E     -
Div/yield     -
EPS -0.23
Shares 545.01M
Beta 1.49
Inst. own 22%
Nov 18, 2015
OPKO Health Inc at Jefferies Autumn Global Healthcare Conference
Nov 9, 2015
Q3 2015 OPKO Health Inc Earnings Call
Nov 9, 2015
Q3 2015 OPKO Health Inc Earnings Release
Sep 29, 2015
OPKO Health Inc at Ladenburg Thalmann Life Sciences Conference
Sep 1, 2015
OPKO Health Inc at Barrington Research Fall Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 92.11% -187.71%
Operating margin -5.75% -160.02%
EBITD margin - -143.64%
Return on average assets 23.27% -12.86%
Return on average equity 36.67% -19.98%
Employees 674 -
CDP Score - -


4400 Biscayne Blvd
MIAMI, FL 33137-3212
United States - Map
+1-305-5754138 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Officers and directors

Phillip Frost M.D. Chairman of the Board, Chief Executive Officer
Age: 80
Bio & Compensation  - Reuters
Jane H. Hsiao Ph.D. Vice Chairman of the Board, Chief Technical Officer
Age: 67
Bio & Compensation  - Reuters
Adam E. Logal Chief Financial Officer, Senior Vice President
Age: 36
Bio & Compensation  - Reuters
Steven D. Rubin Esq. Executive Vice President - Administration, Director
Age: 55
Bio & Compensation  - Reuters
Thomas E. Beier Director
Age: 69
Bio & Compensation  - Reuters
Robert A. Baron Independent Director
Age: 75
Bio & Compensation  - Reuters
Dmitry Yurevich Kolosov Independent Director
Age: 35
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
John A. Paganelli Independent Director
Age: 80
Bio & Compensation  - Reuters